Why did Biogen (BIIB) stock move recently?

On 9/2/2026, Biogen moved +3.1% — Biogen shares rose as Canada’s Drug Agency issued a final positive recommendation supporting public reimbursement of Leqembi (lecanemab) for early Alzheimer’s disease, a key commercial catalyst for the drug co-developed with Eisai. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Biogen (BIIB) overvalued or fairly valued?

MarketChacha shows Biogen's valuation in context — a trailing P/E of about 21.5, a forward P/E of about 14.7, a price-to-book of about 1.9 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Biogen's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.62×) from reported figures — education, not a rating.

What is Biogen's revenue?

Biogen reported revenue of $9.9B for FY2025, with net profit of $1.3B, per official filings.

What is the share price of Biogen (BIIB)?

Biogen last traded at $243.10 (+4.1% on the day), as of 10/20/2026 — a delayed quote shown for education, not investment advice.

Biogen

BIIB · NASDAQ · Healthcare · United States

Snapshot

TickerBIIB

ExchangeNASDAQ

SectorHealthcare

IndustryDrug Manufacturers - General

CountryUnited States

Employees7,500

HeadquartersCambridge, United States

Websitewww.biogen.com

Filings tracked20

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Who owns it

Insiders0.2%
Institutions99.6%
Public & other0.2%

1,490 institutional holders

Ownership breakdown from public market data.

Top holders

FMR, LLC12.33%
Blackrock Inc.10.82%
Primecap Management Company10.26%
Vanguard Capital Management LLC6.53%
State Street Corporation4.97%
Vanguard Portfolio Management LLC4.47%
Geode Capital Management, LLC3.01%
Wellington Management Group, LLP2.11%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Latest ROE of 7.8% is on the low side — the business earns a modest return on shareholder capital.

Cash conversion1.62×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend11.8% → 13.1%

Margin has expanded by about 1.3 points — the business is getting more profitable.

Return on equity7.8%

Latest ROE of 7.8% is on the low side — the business earns a modest return on shareholder capital.

Growth qualityrev 0% · PAT 6%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $2.6B · EPS 3.29

Est. earnings growth +65.4%

Next fiscal year

Rev $10.7B · EPS 16.46

Est. earnings growth +31.7%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$9.9B

Net margin

13.1%

Revenue CAGR (2y)

+0.3%

Profit CAGR (2y)

+5.5%

EPS (FY2025)

8.79

Net profit (FY2025)

$1.3B

Ask MarketChacha about BIIB

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Sep 2, 2026
Biogen shares rose as Canada’s Drug Agency issued a final positive recommendation supporting public reimbursement of Leqembi (lecanemab) for early Alzheimer’s disease, a key commercial catalyst for the drug co-developed with Eisai.
source 1 ↗source 2 ↗source 3 ↗· confidence: high
Aug 4, 2026
Biogen shares rose on continued positive momentum from its July 29 Q2 earnings release and subsequent analyst upgrades citing a strong quarter, with no new material catalyst reported today.
source 1 ↗source 2 ↗source 3 ↗· confidence: medium

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$9.9B	$1.3B	8.79	13.1%	—
FY2024	$9.7B	$1.6B	11.18	16.9%	—
FY2023	$9.8B	$1.2B	7.97	11.8%	7.8%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$2.5B	$319.5M	2.15	12.9%
2025Q3	$2.5B	$466.5M	3.17	18.4%
2025Q2	$2.6B	$634.8M	4.33	24.0%
2025Q1	$2.4B	$240.5M	1.64	9.9%
2024Q3	$2.5B	$388.5M	2.66	15.8%
2024Q2	$2.5B	$583.6M	4.00	23.7%
2024Q1	$2.3B	$393.4M	2.70	17.2%
2023Q3	$2.5B	$-68.1M	-0.47	-2.7%
2023Q2	$2.5B	$591.6M	4.07	24.1%
2023Q1	$2.5B	$387.9M	2.67	15.7%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Exhibits
SEC7/29/2026material
10-Q filing
SEC7/29/2026
8-K — Results of operations
SEC7/1/2026material
8-K/A — Exhibits
SEC6/10/2026
8-K — Shareholder vote results
SEC6/10/2026material
8-K — Material agreement, Completion of acquisition/disposition, Material financial obligation, Reg FD disclosure, Exhibits
SEC5/14/2026material
8-K — Results of operations, Exhibits
SEC4/29/2026material
10-Q filing
SEC4/29/2026
8-K — Results of operations
SEC4/6/2026material
8-K — Material agreement, Other events, Exhibits
SEC3/31/2026material
8-K — Executive/director change
SEC3/11/2026material
8-K — Executive/director change, Other events
SEC2/11/2026material
8-K — Results of operations, Exhibits
SEC2/6/2026material
10-K filing
SEC2/6/2026
8-K — Results of operations
SEC1/14/2026material

2025

8-K — Results of operations, Exhibits
SEC10/30/2025material
10-Q filing
SEC10/30/2025
8-K — Results of operations, Exhibits
SEC10/14/2025material
10-Q filing
SEC7/31/2025
8-K — Results of operations, Exhibits
SEC7/31/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.